Literature DB >> 33540877

Injectable Antiretroviral Drugs: Back to the Future.

Marco Berruti1, Niccolò Riccardi2, Diana Canetti3,4, Sergio Lo Caputo5, Lucia Taramasso6, Antonio Di Biagio1,6.   

Abstract

Current HIV treatment regimens provide sustained virologic suppression, at least partially restore the immune system and have limited side effects; however, they do not allow viral eradication and they are burdened by daily pill intake with a life-long commitment for the people living with HIV (PHIV). Injectable agents might represent a turning point in the care of PHIV, allowing less frequent administration of antiretroviral treatment (ART), more widespread use of pre-exposure prophylaxis (PrEP) and more stable drug levels in the blood, thus increasing the odds to get closer to end the HIV pandemic. The aim of this manuscript is to give a comprehensive review of injectable antiretrovirals that have been used in the past, which are available now, will be available in the future, and their role in the treatment of HIV infection.

Entities:  

Keywords:  ART; HIV; PrEP; antiretroviral; injectable; treatment

Year:  2021        PMID： 33540877      PMCID： PMC7913057          DOI： 10.3390/v13020228

Source DB:  PubMed          Journal:  Viruses        ISSN： 1999-4915            Impact factor:   5.048


  37 in total

1.  Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

Authors:  Anton L Pozniak; Javier Morales-Ramirez; Elly Katabira; Dewald Steyn; Sergio H Lupo; Mario Santoscoy; Beatriz Grinsztejn; Kiat Ruxrungtham; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

2.  Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

Authors:  Susan Swindells; Jaime-Federico Andrade-Villanueva; Gary J Richmond; Giuliano Rizzardini; Axel Baumgarten; Mar Masiá; Gulam Latiff; Vadim Pokrovsky; Fritz Bredeek; Graham Smith; Pedro Cahn; Yeon-Sook Kim; Susan L Ford; Christine L Talarico; Parul Patel; Vasiliki Chounta; Herta Crauwels; Wim Parys; Simon Vanveggel; Joseph Mrus; Jenny Huang; Conn M Harrington; Krischan J Hudson; David A Margolis; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  N Engl J Med       Date:  2020-03-04       Impact factor: 91.245

3.  Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports.

Authors:  Lucia Taramasso; Chiara Dentone; Anna Alessandrini; Bianca Bruzzone; Giancarlo Icardi; Rodolphe Garraffo; Ilaria De Macina; Claudio Viscoli; Antonio Di Biagio
Journal:  Int J STD AIDS       Date:  2014-10-20       Impact factor: 1.359

4.  Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.

Authors:  Brinda Emu; Jeffrey Fessel; Shannon Schrader; Princy Kumar; Gary Richmond; Sandra Win; Steven Weinheimer; Christian Marsolais; Stanley Lewis
Journal:  N Engl J Med       Date:  2018-08-16       Impact factor: 91.245

5.  Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.

Authors:  R Verloes; S Deleu; N Niemeijer; H Crauwels; P Meyvisch; P Williams
Journal:  HIV Med       Date:  2015-05-18       Impact factor: 3.180

6.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

7.  Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.

Authors:  Hongwei Zhang; Ronghua Jin; Cheng Yao; Tong Zhang; Meixia Wang; Wei Xia; Haiyan Peng; Xiaojuan Wang; Rongjian Lu; Changjin Wang; Dong Xie; Hao Wu
Journal:  AIDS Res Ther       Date:  2016-02-10       Impact factor: 2.250

8.  Correction to: Ibalizumab: First Global Approval.

Authors:  Anthony Markham
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

9.  Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.

Authors:  Lucia Taramasso; Antonio Di Biagio; Niccolò Riccardi; Federica Briano; Elisa Di Filippo; Laura Comi; Sara Mora; Mauro Giacomini; Andrea Gori; Franco Maggiolo
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

Review 10.  Long-acting injectable antiretrovirals for HIV treatment and prevention.

Authors:  William R Spreen; David A Margolis; John C Pottage
Journal:  Curr Opin HIV AIDS       Date:  2013-11       Impact factor: 4.283
View more
  3 in total

1.  Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.

Authors:  Andrea De Vito; Annarita Botta; Marco Berruti; Valeria Castelli; Vincenzo Lai; Chiara Cassol; Alessandro Lanari; Giulia Stella; Adrian Shallvari; Antonia Bezenchek; Antonio Di Biagio
Journal:  J Pers Med       Date:  2022-01-31

2.  Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China.

Authors:  Jingmin Nie; Feng Sun; Xuejiao He; Jun Liu; Min Wang; Chongxi Li; Shanqun Gu; Zhong Chen; Ying Li; Yaokai Chen
Journal:  Infect Dis Ther       Date:  2021-09-29

3.  Enhanced Antiviral Ability by a Combination of Zidovudine and Short Hairpin RNA Targeting Avian Leukosis Virus.

Authors:  Qun Wang; Qi Su; Bowen Liu; Yan Li; Wanli Sun; Yanxue Liu; Ruyu Xue; Shuang Chang; Yixin Wang; Peng Zhao
Journal:  Front Microbiol       Date:  2022-02-16       Impact factor: 5.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.